Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open label, phase 1 clinical trial of an intra-dermal booster dose of
INO-4800 alone or in combination with INO-9112 followed by electroporation (EP) among healthy
adults at least 18 years of age, who previously completed their primary series with mRNA
vaccines against SARS-CoV-2 within 6-12 months prior to the booster dose.